• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Expert opinion on pharmacotherapy >An overview of rosuvastatin/ezetimibe association for the treatment of hypercholesterolemia and mixed dyslipidemia
【24h】

An overview of rosuvastatin/ezetimibe association for the treatment of hypercholesterolemia and mixed dyslipidemia

机译：罗苏瓦司汀/欧扎特米贝治疗高胆固醇血症和混合血脂血症综合症概述

获取原文
获取原文并翻译 | 示例
       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Introduction: Although statin therapy is a powerful lipid-lowering strategy, only one-fifth of statin users currently reach their lipid goals. In addition, statin treatment alone has relatively low efficacy in reducing other lipid fractions than low-density lipoprotein-cholesterol (LDL-C). In such cases, most guidelines recommend adding the cholesterol absorption inhibitor ezetimibe. Areas covered: This paper summarizes the main pharmacological characteristics of rosuvastatin and ezetimibe (mechanism of action, metabolism), their lipid-lowering and pleiotropic effects, with particular attention to the clinical effects of the combined drugs in hypercholesterolemia and mixed dyslipidemia patients (such as the ones affected by diabetes mellitus and Acquired Immune Deficiency Syndrome (AIDS)). Expert opinion: The additive effect of rosuvastatin and ezetimibe helps to reach lipid goals in a large number of high-risk patients, while avoiding some safety issues related to high dosages of intensive statin therapy. Patients with diabetes receive additional benefits from ezetimibe as they seem to absorb cholesterol more effectively than non-diabetic ones, because of increased NPC1L1 gene expression. Ezetimibe augments rosuvastatin triglyceride-lowering and anti-inflammatory effects, as well. Taking into account its excellent safety profile and lack of clinically relevant drug-drug interactions, the rosuvastatin/ezetimibe association is a valuable alternative to statin dose uptitration.
机译：介绍：虽然他汀类药物治疗是一种强大的脂质降低策略，但他汀类药物的五分之一目前只达到他们的脂质目标。此外，单独的他汀蛋白处理在减少除低密度脂蛋白 - 胆固醇（LDL-C）的其他脂质级分中具有相对低的功效。在这种情况下，大多数指南建议添加胆固醇吸收抑制剂Ezetimibe。本文涵盖的区域：罗萨伐他汀和ezetimibe（作用机制，新陈代谢），脂质降低和脂肪疗法的主要药理特征，特别关注高胆固醇血症和混合血脂血症患者的临床影响（如受糖尿病影响的人和获得的免疫缺乏综合征（艾滋病））。专家意见：Rosuvastatin和Ezetimibe的添加剂效应有助于在大量高风险患者中达到脂质目标，同时避免与高剂量的汀类药物治疗有关的一些安全问题。糖尿病患者从ezetimibe获得额外的益处，因为它们似乎比非糖尿病患者更有效地吸收胆固醇，因为NPC1L1基因表达增加。 ezetimibe同时增加甘油三酯甘油三酯 - 降低和抗炎作用。考虑到其优异的安全性曲线和缺乏临床相关的药物 - 药物相互作用，罗斯司汀/欧替米贝协会是他汀类药物剂量高兴的有价值的替代品。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号